NCT02410369

Study of S-588410 After Adjuvant Chemotherapy for Completely Resected Non-small- Cell Lung Cancer

Phase II Study of S-588410 as Maintenance Monotherapy After Adjuvant Chemotherapy in Patients With Completely Resected Non-small- Cell Lung Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Tokyo University · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

In this clinical study, the investigators evaluate the efficacy and safety of S-588410 in patients who underwent an adjuvant chemotherapy after the complete resection of non-small-cell lung cancer.

Detailed description

In this phase II trial, the investigators evaluate the efficacy and safety of S-588410 containing oncoantigens-derived HLA-A\*2402-restricted epitope peptides in patients with HLA-A\*2402 who underwent an adjuvant chemotherapy after the complete resection of non-small-cell lung cancer.

Conditions

• Non-small- Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	S-588410	Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of S-588410.
DRUG	Placebo	Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of Placebo.

Timeline

• Start date: 2015-03-01
• Primary completion: 2020-03-01
• Completion: 2021-09-01
• First posted: 2015-04-07
• Last updated: 2017-12-21

Locations

1 site across 1 country: Japan